Table 1.
Demographical and clinical characteristics of participants.
| Characteristic | Responders (n = 28) | Non-Responders (n = 29) | P values |
|---|---|---|---|
| Age (y) | 31.0 ± 10.2 | 29.7 ± 8.5 | .61 |
| Gender (M/F) | 17/11 | 20/9 | .51 |
| Education level (y) | 11.7 ± 3.5 | 11.3 ± 4.0 | .71 |
| Duration of illness (y) | 5.4 ± 6.4 | 6.1 ± 6.4 | .67 |
| Time between measurements (w)a | 3.9 ± 1.1 | 3.9 ± 1.1 | .89 |
| CGI score at baseline | 5.6 ± 1.1 | 5.7 ± 0.6 | .72 |
| CGI score after ECT | 2.6 ± 0.7 | 3.6 ± 0.9 | <.001 |
| PANSS score at baseline | |||
| Positive score | 29.9 ± 6.2 | 28.0 ± 8.1 | .32 |
| Negative score | 19.5 ± 10.3 | 29.0 ± 10.9 | .001 |
| General score | 44.7 ± 12.1 | 41.7 ± 9.5 | .31 |
| Total score | 94.1 ± 19.2 | 98.7 ± 21.0 | .39 |
| PANSS score after ECT | |||
| Positive score | 9.7 ± 2.0 | 15.4 ± 3.5 | <.001 |
| Negative score | 10.6 ± 4.9 | 19.7 ± 7.9 | <.001 |
| General score | 19.7 ± 3.4 | 28.6 ± 6.7 | <.001 |
| Total score | 40.0 ± 7.1 | 63.7 ± 13.8 | <.001 |
| Changes in PANSS score | 84.7% ± 9.6% | 51.0% ± 12.8% | <.001 |
| Number of ECTa | 10.3 ± 2.0 | 10.0 ± 2.9 | .67 |
| Antipsychotic dose (mg/d)b | 17.5 ± 5.9 | 13.8 ± 6.7 | .03 |
a
Data missing for one non-responder.
b
Olanzapine equivalents based on defined daily doses method.
CGI, Clinical Global Impressions; ECT, electroconvulsive therapy; PANSS, Positive And Negative Syndrome Scale.